what is a glp-1 receptor agonist agonists review and effects A schematic overview of GLP-1

Available at: European Food Safety Authority

Fenfluramine, one of the earliest weight loss drugs, was found over time to be associated with valvular heart disease [48] and was withdrawn from the market by the FDA

For instance, retrospective analyses have suggested potential associations with thyroid cancer risk during long-term use [4], whereas studies of pancreatic cancer have yielded contrasting results [6,7,8]

Safety studies have evaluated single doses up to 0.4 grams per kilogram of body weight (approximately 28 grams for a 70-kilogram adult) without serious adverse effects, though gastrointestinal symptoms represent the primary tolerability concern

Wojcik C, Warden BA

These molecules elicited additive effects to reduce weight and improve glucose control beyond the loose combination of pharmacokinetically and potency-matched GLP-1R and GIPR mono-agonists